#Japan #Tokyo #Ipsen #Seigo Noda

Ipsen Announces Leadership Change with Seigo Noda as New CEO

Ipsen Japan, headquartered in Tokyo, has made a significant announcement regarding its executive leadership. Effective January 1, 2026, Seigo Noda has been appointed as the new Chief Executive Officer (CEO) of the company. This strategic move is expected to reinforce the company's operational foundation in Japan while deepening collaboration with Ipsen's global strategies.

Seigo Noda's Professional Background

Seigo Noda brings a wealth of experience to his new role at Ipsen. After graduating from university, Noda began his career at Sumitomo Corporation Leasing, where he specialized in operating leases and structured finance. His next significant step was with General Electric (GE), where he joined the Experienced Commercial Leadership Program. Post-completion, he held multiple leadership positions in companies such as GE Capital Japan, focusing mainly on the marketing department and strategic initiatives.

In 2013, Noda transitioned to AstraZeneca, where he contributed significantly to the commercial sector and strategic planning departments. Over the years, he played a pivotal role in developing go-to-market strategies across various disease areas in Japan, alongside executing several global initiatives. Most recently, he served as the business head at Alexion Pharmaceuticals Japan, overseeing the amyloidosis sector, where he led successful organizational transformations.

Noda's expertise spans a diverse range of fields, from primary care to rare diseases, indicating his commitment to meeting the unique needs of Japanese patients. His comprehensive background in strategic planning and product value enhancement is expected to guide Ipsen towards continued success in the evolving pharmaceutical landscape.

Vision for Ipsen Japan

In his acceptance of the CEO role, Noda shared his thoughts on leading Ipsen, stating, "I am truly honored to have the opportunity to lead the Japan business as CEO of Ipsen. Founded in 1929, Ipsen is a long-standing pharmaceutical company committed to delivering innovative drugs in the fields of oncology, rare diseases, and neuroscience. We will focus on providing new treatment options for pediatric patients in the rare disease and rare cancer sectors. Our mission is to deliver innovative medicines for patients suffering from rare diseases and their families."

Noda's commitment to improving patient care and enhancing the quality of products reflects Ipsen's dedication to healthcare.

About Ipsen

Ipsen, an international biopharmaceutical company, is dedicated to providing innovative medicines in the fields of oncology, rare diseases, and neuroscience. The company's robust pipeline is bolstered by innovative outcomes and technologies from external sources, sustained by nearly a century of development experience and global networks based in the U.S., France, and the UK. With a commitment and partnership spanning over 40 countries, Ipsen efficiently delivers medicines to more than 100 countries.

Ipsen is publicly listed in Paris (Euronext: IPN) and is also traded in the U.S. through Level I American Depository Receipts (ADR: IPSEY). For further insight into Ipsen, please visit ipsen.com.

Conclusion

As Seigo Noda steps into this vital position at Ipsen Japan, there is great anticipation surrounding how his experience will shape the company’s future and its impact on patient care. Ipsen is poised to continue its historical commitment to drug innovation and making a meaningful difference in the lives of patients worldwide.